Influenza

The approval for Abrysvo represents the second RSV vaccine approved for adults aged 60 years and older in the last month.

New surveillance data from the 2021-22 influenza show the impact of coinfection among younger patients.

A discussion was held regarding research on the use of antivirals on younger influenza patients.

Research upholds prior recommendations for treating younger patients hospitalized with influenza.

The newest indications for the novel oral antiviral drug will make it available as an acute treatment and prophylaxis for children this flu season.

Analysis of patient-reported outcomes last flu season show an approximate 10% increased risk of mild vaccination reactions when receiving both a COVID-19 booster and flu shot instead of a lone booster dose.

The company reported interim results at a meeting this week showing multiple formulations were tolerable and safe. Next comes a phase 2 trial.

No difference in the primary outcome was observed between those randomized to influenza vaccine compared to placebo.

Males between 50-64 who have been vaccinated without erythema were at the highest risk of GBS.

Previously, few rapid diagnostic tests have been studied in home environments, and there are currently no tests approved for at-home influenza detection by the Food and Drug Administration (FDA)

Nearly all of the doctors polled recommended the pneumococcal vaccine for patients with cardiovascular disease aged 65 years and older.

Investigators conducted the largest study on SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses.

Data from Australia show a T-cell antigen-inducing vaccine was unable to provide greater prevention of flu incidence than a placebo.

Evidence-informed interventions were suggested to improve influenza vaccination rates in pregnant women in addition to local and national guidelines.

Investigators suggested that prediction tools such as the decision-making support tool PREDAFLU could be used to provide early warnings of increased activity during these visits.

Findings suggest mortality risk from the respiratory virus is twice greater among adults with CHF.

As influenza A(H3N2) remains the most prevalent subtype in the US, investigators estimated the available flu shot is not significantly preventing positive cases.

Influenza mortality rates have not been updates since the last estimate in 2009.

The CDC has estimated at least 2.4 million flu illnesses, 23,000 hospitalizations, and 1,400 deaths from flu so far this season.

Obesity was added to the list of risk factors for influenza in 2009.

More than 40% of community-acquired and 70% of hospital-acquired influenza inpatients experienced intrahospital bed transfers during their active infection period.

A new study suggests even the phrasing of telemedicine notifications may make a difference in vaccine uptake.

A Finnish national study suggests hard-to-reach adults may seek a flu shot if provided direct information on its benefits.

The application for NVX-CoV2373 is supported by promising data from 2 multinational trials conducted prior to the spread of the Omicron variant.